ArticleLaryngoscope investigative otolaryngology2026
Missed Opportunities in Head and Neck Cancer Prevention: Human Papillomavirus Vaccination Messaging in MENA-Serving Health Systems.
Article in Laryngoscope investigative otolaryngology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To analyze the presence, framing, and cultural accessibility of HPV vaccination messaging related to oropharyngeal squamous cell carcinoma (OPSCC) prevention among health institutions serving Middle Eastern and North African (MENA) populations in the United States. Materials and Methods: Cross-sectional content analysis of publicly available HPV vaccination materials from 37 MENA-serving institutions (24 health systems, eight public health departments, five community-based organizations) across eight U.S. metropolitan counties selected using 2020 U.S. Census-derived MENA population estimates. Reporting followed SRQR guidelines. Primary outcomes included presence of head and neck cancer language, HPV-16 mention, cervical cancer-dominant framing, Arabic/Farsi/Turkish language access, and cultural tailoring. Results: Twenty-six of 37 institutions (70.3%) provided HPV vaccination content. Among these, 14 (53.8%) included head and neck cancer language and only 4 (15.4%) mentioned HPV-16. A cervical cancer-dominant framework was present in 13 (50.0%). Eight institutions (30.8%) offered Arabic, Farsi, or Turkish language access. Cultural tailoring was present in 12 (46.2%). No community-based organizations provided HPV vaccination content. Conclusion: HPV vaccination messaging among MENA-serving institutions inadequately reflects OPSCC epidemiology. Head and neck cancer language, HPV-16 mention, language access, and cultural tailoring remain inconsistent. Otolaryngologists are well positioned to advocate for cancer-inclusive, culturally responsive HPV prevention messaging. Level of Evidence: 4.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.